000 02224na a2200277 4500
003 PC3665
005 20180417112257.0
008 130622s2012 xxx||||| |||| 00| 0 eng d
040 _cH120
041 _aeng, spa
100 _9387
_aCortijo Cascajares, Susana
_eFarmacia
100 _aAmuriza Chicharro, Natalia de
_91997
_eFarmacia
100 _9875
_aHerreros de Tejada López-Coterilla, Alberto
_eFarmacia
100 _aAguilella Vizcaíno, María José
_91920
_eFarmacia
100 _91925
_aGoyache Goñi, María del Puy
_eFarmacia
100 _aGastalver Martín, Cristina
_92001
_eFarmacia
245 0 0 _aAnalysis of Panitumumab Use in the Clinical Practice
_h[artículo]
260 _bAtención Farmaceútica,
_c2012
300 _a2012:14(4):270-5.
500 _aFormato Vancouver: Gastalver Martín C, Cortijo Cascajares N, De Amuriza Chicharro N, Aguilella Vizcaíno MJ, Goyache-Goñi MP, Herreros de Tejada López Coterilla A. Análisis de utilización de Panitumumab en la práctica clínica. Aten Farm. 2012:14(4):270-5.
520 _aObjective: To understand panitumumab use and safety in the clinical practice. Method: We conducted a retrospective study in the years 2009 and 2010, which included all those patients who had received panitumumab during this period. The collected variables were age, prior treatments, number of cycles, dose, pattern, changes in dose and pattern, adverse effects and cause for treatment suspension. Results: We found that the majority of patients received panitumumab after other treatments failed. 48% of the population took panitumumab combined with other medications. The most common adverse reactions were dermatological. The adverse reaction profile did not vary in a significant way between the two types of administration. 13.4% of patients who received panitumumab were suffering from head and neck cancer Conclusions: We observed an extended use of panitumumab in a polytherapy regime. This last one was more effective than in monotherapy, with a slightly higher toxicity.
710 _9320
_aServicio de Farmacia Hospitalaria
773 0 _g
856 _uhttp://pc-h12o-es.m-hdoct.a17.csinet.es/pdf/pc/3/pc3665.pdf
_ySolicitar documento
942 _n0
_2ddc
_cART
999 _c3665
_d3665